Issues related to the Rare Pediatric Disease Priority Review Voucher (PRV) Program; Rare disease drug development
2026 · 3rd Quarter (July 1 - Sep 30)
DENALI THERAPEUTICS
Filed by MANATT, PHELPS, AND PHILLIPS.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 5, 2026
- Income
- $70,000.00
- Expenses
- Not reported
- Registrant
- MANATT, PHELPS, AND PHILLIPS
- Client
- DENALI THERAPEUTICS
- Filing UUID
- 14418425-34f1-44a1-b500-5cff91aa481f
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.